HILE(SH:603718) Xin Lang Cai Jing·2025-06-13 10:23Summary of Key Points - The core viewpoint of the article is that Han Benyi, the director and general manager of Shanghai Haili Biotechnology Co., Ltd., did not execute his planned share reduction by the deadline, resulting in no shares being sold [1]. Group 1: Shareholding Situation Before Reduction - Before the planned reduction, Han Benyi held 3 million shares, accounting for 0.4560% of the company's original total share capital [2]. - Following the company's repurchase and cancellation of restricted shares on April 15, 2025, the total share capital changed to 655,662,200 shares, and Han Benyi's holdings were reduced to 2.73 million shares, representing 0.4164% of the total share capital [2]. Group 2: Details of the Reduction Plan - On February 20, 2025, the company announced Han Benyi's share reduction plan, which was set to occur from March 14, 2025, to June 13, 2025, allowing for a maximum reduction of 750,000 shares, or 0.1140% of the total share capital, and not exceeding 25% of his holdings [3]. - Due to the repurchase of restricted shares, Han Benyi's available shares for reduction were adjusted to a maximum of 682,500 shares [3]. Group 3: Results of the Reduction Implementation - As of June 14, 2025, the announcement date, Han Benyi did not reduce any shares, with a total reduction of 0 shares and a reduction price range of 0 - 0 CNY/share, resulting in a total amount of 0 CNY [4]. - The actual reduction situation aligned with the previously disclosed reduction plan, and the reduction period expired without any shares being sold, nor was the reduction plan terminated early [4].